SD
REGN icon

Sumway Development’s Regeneron Pharmaceuticals REGN Stock Holding History

Sumway Development’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-17,689
Closed -$7.91M – 9
2017
Q3 		$7.91M Hold
17,689
– – 1.85% 7
2017
Q2 		$8.69M Buy
17,689
+7,889
+81% +$3.45M 2.13% 9
2017
Q1 		$3.63M Buy
9,800
+1,200
+14% +$445K 1.6% 9
2016
Q4 		$3.21M Hold
8,600
– – 1.45% 8
2016
Q3 		$3.46M Hold
8,600
– – 1.4% 8
2016
Q2 		$3M Buy
+8,600
New +$3.31M 1.54% 7

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Sumway Development's REGN Position: Q4 2017 in Review

Sumway Development sold out of Regeneron Pharmaceuticals (REGN) in Q4 2017, closing a stake of 17,689 shares — an estimated $7.91M sold.

Sumway Development first reported a position in REGN in Q2 2016 and held it in 6 quarters. The position peaked at $8.69M in Q2 2017. 639 funds tracked by Wall St. Rank hold REGN as of Q4 2017.

  • Sumway Development reported no remaining Regeneron Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Sumway Development sold 17,689 Regeneron Pharmaceuticals shares in Q4 2017, an estimated $7.91M.
  • Sumway Development first reported a position in Regeneron Pharmaceuticals in Q2 2016 and held it in 6 quarters.
  • Sumway Development's Regeneron Pharmaceuticals position peaked at $8.69M in Q2 2017.
  • 639 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2017.

Based on Sumway Development's 13F filing for Q4 2017.